Selinexor

Solid Tumor

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 59/ 100

Competitive context

927 Active assets in the Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Glycopyrrolate Medical College of Wisconsin	Phase 4	BB
VITAMIN D Tanta University	Phase 4	BB
Bxcl501 Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant

BBB

Indicative ·

72 / 100

mantle cell lymphomaDormant

BB

Indicative ·

70 / 100

relapsed/refractory diffuse large B-cell lymphomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.